AstraZeneca
AstraZeneca is a high-quality pharma company with a strong portfolio of commercial products that lead to better overall health outcomes for patients, who are often suffering from life-threatening or debilitating illness. The company's products treat a broad range of issues and target areas of high unmet need, particularly in the oncology and rare disease portfolios.
Visit their site- Enterprise value
- US$231.5 bn
- Region
- UK
- Theme
- Health
- Sub-theme
- Pharmaceutical therapies
Impact Score
AstraZeneca has a diverse portfolio of therapies, often treating life threatening or rare diseases. In lung cancer the five year survival rate is only 24%, for example, however this has improved from a mere 5% in c. 2018. This is, in part, thanks to a number of AstraZeneca’s drugs that have received breakthrough designation from the FDA which means that they have shown evidence of substantial improvement in serious conditions.
Fundamental Quality
The disease areas AstraZeneca focuses on have strong structural growth drivers from ageing populations and lifestyle factors. The company has consistently demonstrated industry-leading returns on R&D investment and the strong pipeline is supportive of future growth. Healthcare access is central within its sustainability policy as seen via affordability programmes in over 20 low- and middle- income countries.
UN SDGs
AstraZeneca’s therapies support SDG 3 in the context of reducing mortality form non-communicable diseases through treatment.
Find out moreRisk of negative impacts
- Side-effects from pharmaceuticals
- Product pricing restricts access for poor communities
- Plastic waste from packaging
- Animal testing of pharmaceuticals
Related insights Related
Sustainable
The next constraint on AI is not just energy, it's also water
By Ty Lee
10 Mar 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
By WHEB Investment Team
17 Feb 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
By WHEB Investment Team
19 Jan 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
By Seb Beloe
19 Jan 2026 | 5 min read